title: The protective effect of MCP-1 -2518 A>G promoter polymorphism in Turkish chronic renal failure patients requiring long-term hemodialysis.
abstract: OBJECTIVE
  Monocyte chemoattractant protein-1 (MCP-1) plays a major role in the pathogenesis and progression of different types of human renal disease. Therefore, in this study, we aimed to investigate the effect of MCP-1 gene -2518 A>G promoter polymorphism in chronic renal failure (CRF) patients requiring long-term hemodialysis.
  
  
  METHODS
  The study population consisted of 201 adult CRF patients requiring long-term hemodialysis and 194 healthy controls. The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique was used for genotyping of MCP-1 -2518 A>G polymorphism in the CRF patients and healthy controls.
  
  
  RESULTS
  There were statistically significant differences in terms of genotypic (χ (2) = 12.69, p = 0.02) and allelic (χ (2) = 5.72, p = 0.02) frequencies of MCP-1 -2518 A>G between CRF patients and control subjects. According to our results, in the patient group MCP-1 -2518 AA genotype frequency was significantly higher than that of control group. On the other hand, heterozygous AG genotype frequency in the control group was significantly higher than that of the study group. Three different main disease subgroups of CRF (hypertension, diabetes mellitus, and atherosclerosis) patients were also evaluated, and significant associations were found between hypertension (genotype: χ (2) = 9.28, p = 0.01; allele: χ (2) = 6.00, p = 0.01), atherosclerosis (genotype: χ (2) = 5.37, p = 0.02; allele: χ (2) = 4.13, p = 0.04), and distributions of MCP-1 -2518 A>G genotypes and alleles. However, no significant association was found between diabetes mellitus and distributions of MCP-1 -2518 A>G genotype and allele frequencies (genotype: χ (2) = 2.37, p = 0.3; allele: χ (2) = 1.88, p = 0.17).
  
  
  CONCLUSIONS
  Current data show that MCP-1 -2518 AA genotype may cause susceptibility to CRF, while G allele may have a protective effect against development of CRF. In addition, MCP-1 -2518 AA genotype seems to associate with CRF originated from hypertension and atherosclerosis in our study population.
authors: Department of Nutrition and Dietetics, Faculty of Health Sciences, Cumhuriyet University, Sivas, Turkey, binnur.koksal@hotmail.com.
authors: Binnur
authors: B
authors: Bagci
authors: Gokhan
authors: G
authors: Bagci
authors: Ferhan
authors: F
authors: Candan
authors: Ozturk
authors: O
authors: Ozdemir
authors: Ilhan
authors: I
authors: Sezgin
mesh_terms: D000328:Adult; D000368:Aged; D050197:Atherosclerosis / Q000150:complications / Q000235:genetics; D016022:Case-Control Studies; D018932:Chemokine CCL2 / Q000235:genetics*; D003928:Diabetic Nephropathies / Q000235:genetics; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000235:genetics; D007676:Kidney Failure, Chronic / Q000150:complications / Q000235:genetics* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D006435:Renal Dialysis; D013997:Time Factors; D014421:Turkey
chemical_list: C111835:CCL2 protein, human; D018932:Chemokine CCL2
references: Exp Mol Med. 2007 Aug 31;39(4):499-507
references: 17934338
references: Cytokine. 2008 Dec;44(3):361-5
references: 19014891
references: Bratisl Lek Listy. 2010;111(8):420-5
references: 21033620
references: Intern Med. 2011;50(21):2457-61
references: 22041342
references: J Exp Med. 1999 Dec 20;190(12):1813-24
references: 10601356
references: Kidney Int. 2000 Jan;57(1):129-36
references: 10620194
references: J Am Soc Nephrol. 2000 Jan;11(1):152-76
references: 10616852
references: J Am Soc Nephrol. 2002 Oct;13(10):2585-9
references: 12239249
references: Clin Chim Acta. 2011 Nov 20;412(23-24):2022-30
references: 21851811
references: J Clin Invest. 1999 Jan;103(1):73-80
references: 9884336
references: Kobe J Med Sci. 2008 Feb 08;53(6):345-54
references: 18762729
references: ScientificWorldJournal. 2005 Sep 29;5:835-44
references: 16200331
references: Arterioscler Thromb Vasc Biol. 2002 Jun 1;22(6):914-20
references: 12067898
references: Hypertension. 1995 Feb;25(2):155-61
references: 7843763
references: Curr Opin Lipidol. 2004 Oct;15(5):553-8
references: 15361791
references: Hypertens Res. 2003 Sep;26(9):677-83
references: 14620921
references: Arthritis Rheum. 2001 Sep;44(9):2211-2
references: 11592387
references: Kidney Int. 2006 Apr;69(7):1189-97
references: 16609683
references: J Korean Med Sci. 2007 Aug;22(4):611-5
references: 17728497
references: J Rheumatol. 2010 Apr;37(4):776-82
references: 20231199
references: Clin Exp Nephrol. 2005 Dec;9(4):297-303
references: 16362156
references: Genet Test Mol Biomarkers. 2013 Oct;17(10):750-5
references: 23930970
references: J Korean Med Sci. 2007 Oct;22(5):810-4
references: 17982227
references: Arch Immunol Ther Exp (Warsz). 2004 May-Jun;52(3):164-72
references: 15247883
references: Am J Physiol Renal Physiol. 2008 Apr;294(4):F697-701
references: 18272603
references: Ren Fail. 2015 Mar;37(2):292-6
references: 25394530
references: Nephrol Dial Transplant. 2004 Mar;19(3):596-601
references: 14767014
references: Transplant Proc. 2008 Dec;40(10):3359-61
references: 19100389
references: J Immunol. 2000 Nov 1;165(9):4877-83
references: 11046012
references: Kidney Int. 2005 Aug;68(2):437-55
references: 16014021
references: Biochem Biophys Res Commun. 1999 Jun 7;259(2):344-8
references: 10362511
references: Diabetes Res Clin Pract. 2009 Dec;86(3):193-8
references: 19781803
references: J Interferon Cytokine Res. 2009 Jun;29(6):313-26
references: 19441883
references: Hypertension. 1997 Dec;30(6):1397-402
references: 9403559
references: J Am Soc Nephrol. 2002 Jun;13(6):1534-47
references: 12039983